Opportunity radar
4,186,134 patents indexed · 165,974,948 citations · issued 2005-01-04 → 2026-05-05
Showing50 of 30,058
Pharma (A61K)Therapy methods (A61P)Med devices (A61M)Agriculture (A01)Hand tools (B25)Consumer (A47)Energy (H01M)AI / ML (G06N)
| Patent # | Title | Assets | Issued | Expires | Fwd cites | Score |
|---|---|---|---|---|---|---|
| 12565494 | Inhibitors of human respiratory syncytial virus and metapneumovirus | 🖼🧊📄§ | 2026-03-03 | 2043-05-11 | 0 | 31 |
| 12564581 | Pyrazole pharmaceutical composition | 🖼🧊📄§ | 2026-03-03 | 2040-12-18 | 0 | 31 |
| 12564641 | Eribulin antibody-drug conjugates and methods of use | 🖼🧊📄§ | 2026-03-03 | 2042-12-23 | 0 | 31 |
| 12564597 | Ibogaine analogs as therapeutics for neurological and psychiatric disorders | 🖼🧊📄§ | 2026-03-03 | 2041-03-04 | 0 | 31 |
| 12564596 | Agents and methods for modulating pathogen activity | 🖼🧊📄§ | 2026-03-03 | 2039-09-30 | 0 | 31 |
| 12564625 | Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus CHIKV-Δ5nsP3 | 🖼🧊📄§ | 2026-03-03 | 2044-05-06 | 0 | 31 |
| 12564572 | Topical ocular delivery of cromakalim | 🖼🧊📄§ | 2026-03-03 | 2044-10-04 | 0 | 31 |
| 12564611 | Pancreatic endocrine progenitor cells and use thereof | 🖼🧊📄§ | 2026-03-03 | 2040-09-17 | 0 | 31 |
| 12564588 | HECT E3 ubiquitin liagase inhibitors and uses thereof | 🖼🧊📄§ | 2026-03-03 | 2042-01-21 | 0 | 31 |
| 12564574 | Pharmaceutical composition for preventing or treating parkinson's disease, comprising 2-(4-(1-hydroxypropane-2-yl)phenyl)isoindoline-1-one compound | 🖼🧊📄§ | 2026-03-03 | 2041-03-25 | 0 | 31 |
| 12565499 | Compounds and methods | 🖼🧊📄§ | 2026-03-03 | 2044-03-11 | 0 | 31 |
| 12565653 | ATAXIN3 (ATXN3) RNAi agent compositions and methods of use thereof | 🖼🧊📄§ | 2026-03-03 | 2040-11-20 | 0 | 31 |
| 12565523 | Structure-guided engineering of peptide-based NLRP3 inflammasome inhibitors for myelodysplastic syndromes (MDS) | 🖼🧊📄§ | 2026-03-03 | 2040-05-01 | 0 | 31 |
| 12564586 | Kappa opiod receptor antagonists for treating pain-related sleep disorders | 🖼🧊📄§ | 2026-03-03 | 2041-04-09 | 0 | 31 |
| 12564563 | Composition and methods for treating pathogenic infections on wounds | 🖼🧊📄§ | 2026-03-03 | 2040-12-22 | 0 | 31 |
| 12564615 | Treatment method for cardiac hypertrophy | 🖼🧊📄§ | 2026-03-03 | 2043-12-19 | 0 | 31 |
| 12564624 | Ostrich antibody for bacterial infectious diseases | 🖼🧊📄§ | 2026-03-03 | 2044-04-11 | 0 | 31 |
| 12565531 | Bispecific fusion protein for tumor treatment | 🖼🧊📄§ | 2026-03-03 | 2040-12-03 | 0 | 31 |
| 12564600 | System for enhancing therapeutic compliance of the anti-cancer compound E7766 | 🖼🧊📄§ | 2026-03-03 | 2040-07-01 | 0 | 31 |
| 12564598 | Nitric oxide-sensitive hydrogel | 🖼🧊📄§ | 2026-03-03 | 2042-01-10 | 0 | 31 |
| 12564622 | Preventing cytokine release syndrome | 🖼🧊📄§ | 2026-03-03 | 2042-12-09 | 0 | 31 |
| 12564610 | Human periventricular endothelial cell therapy for neuropsychiatric disorders | 🖼🧊📄§ | 2026-03-03 | 2040-10-19 | 0 | 31 |
| 12564631 | Phytosphingosine derivatives as adjuvants in immune stimulation | 🖼🧊📄§ | 2026-03-03 | 2041-06-18 | 0 | 31 |
| 12564606 | Pharmaceutical composition for treating wounds | 🖼🧊📄§ | 2026-03-03 | 2039-11-21 | 0 | 31 |
| 12565660 | Immunomodulating transgenic plants and related methods | 🖼🧊📄§ | 2026-03-03 | 2044-01-24 | 0 | 31 |
| 12564560 | Selective serotonin receptor modulators and methods of making and using the same | 🖼🧊📄§ | 2026-03-03 | 2045-04-02 | 0 | 31 |
| 12564608 | Use of ghost nanovesicles as therapeutics | 🖼🧊📄§ | 2026-03-03 | 2040-09-11 | 0 | 31 |
| 12564591 | HCK as a therapeutic target in MYD88 mutated diseases | 🖼🧊📄§ | 2026-03-03 | 2040-10-07 | 0 | 31 |
| 12564616 | Composition for respiratory diseases | 🖼🧊📄§ | 2026-03-03 | 2044-04-19 | 0 | 31 |
| 12564617 | Methods for modulating macrophage activity | 🖼🧊📄§ | 2026-03-03 | 2041-09-17 | 0 | 31 |
| 12565654 | Extracellular vesicle secretion reducing agent for reducing extracellular vesicle secretion, and use of the same | 🖼🧊📄§ | 2026-03-03 | 2041-04-07 | 0 | 31 |
| 12564599 | Pharmaceutical composition comprising tetrahydrocannabivarin for the prevention and treatment of overweight | 🖼🧊📄§ | 2026-03-03 | 2040-02-21 | 0 | 31 |
| 12565651 | Oligonucleotides comprising segmented gap structures | 🖼🧊📄§ | 2026-03-03 | 2044-07-10 | 0 | 31 |
| 12564614 | Pharmaceutical composition based on plant extracts for the treatment of fibromyalgia, rheumatoid arthritis, lupus and other autoimmune diseases | 🖼🧊📄§ | 2026-03-03 | 2040-06-18 | 0 | 31 |
| 12565535 | Chimeric antigen receptors targeted to PSCA | 🖼🧊📄§ | 2026-03-03 | 2042-08-17 | 0 | 31 |
| 12565533 | Agonistic CD40 antibodies | 🖼🧊📄§ | 2026-03-03 | 2043-05-25 | 0 | 31 |
| 12564626 | Serum free intracellular pathogen vaccine | 🖼🧊📄§ | 2026-03-03 | 2039-12-20 | 0 | 31 |
| 12564620 | Treatment of gulf war illness | 🖼🧊📄§ | 2026-03-03 | 2042-09-15 | 0 | 31 |
| 12564580 | Mitochondria-targeted isoketal/isolevuglandin scavengers and uses thereof | 🖼🧊📄§ | 2026-03-03 | 2041-01-27 | 0 | 31 |
| 12565648 | MicroRNA-mediated methods for rejuvenating CNS glial populations | 🖼🧊📄§ | 2026-03-03 | 2042-10-19 | 0 | 31 |
| 12564571 | Compositions and methods for the treatment of equine protozoal myeloencephalitis | 🖼🧊📄§ | 2026-03-03 | 2039-02-20 | 0 | 31 |
| 12564567 | Antiviral therapeutic compounds and compositions for use in treatment of coronavirus and influenza virus | 🖼🧊📄§ | 2026-03-03 | 2043-11-27 | 0 | 31 |
| 12565476 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | 🖼🧊📄§ | 2026-03-03 | 2043-03-21 | 0 | 31 |
| 12565501 | Muscarinic acetylcholine M1 receptor antagonists | 🖼🧊📄§ | 2026-03-03 | 2040-10-06 | 0 | 31 |
| 12565522 | Micropeptide HMMW and application thereof | 🖼🧊📄§ | 2026-03-03 | 2040-11-03 | 0 | 31 |
| 12565528 | LAG-3 antagonist therapy for lung cancer | 🖼🧊📄§ | 2026-03-03 | 2044-06-28 | 0 | 31 |
| 12564633 | Oncolytic virus strain | 🖼🧊📄§ | 2026-03-03 | 2044-05-21 | 0 | 31 |
| 12564576 | Therapeutic agent for vascular disorder | 🖼🧊📄§ | 2026-03-03 | 2041-05-07 | 0 | 31 |
| 12564595 | Prophylactic and therapeutic pharmaceutical agent for HIV infectious diseases characterized by comprising combination of integrase inhibitor and anti-HIV agent | 🖼🧊📄§ | 2026-03-03 | 2040-11-27 | 0 | 31 |
| 12564582 | Use of pridopidine for treating dystonias | 🖼🧊📄§ | 2026-03-03 | 2043-10-19 | 0 | 31 |